AI Article Synopsis
- Kidney transplant recipients are more susceptible to severe COVID-19 and the study assessed their antibody response after a third vaccine dose.
- The third dose increased seroconversion rates, but many showed limited neutralizing antibodies, especially against the Omicron variant.
- Factors like immunosuppressive medication, older age, and poorer kidney function negatively impacted vaccination effectiveness, suggesting a need for careful management of immunosuppressants for better vaccine response while balancing rejection risks.
Article Abstract
Unlabelled: Kidney transplant recipients are at increased risk of SARS-CoV-2 infection and a more severe course of COVID-19.
Methods: We conducted a quantitative serologic testing of antibodies specific for the wild type of SARS-CoV-2 and the Omicron variant of concern before and after a third-dose vaccination, either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) in a cohort of 103 stable kidney transplant recipients (median [range] age, 58 [22-84] y, 57 men [55.3%]).
Results: Third-dose vaccination increased the seroconversion rate from 57.3% to 71.8%. However, despite a marked rise of the antibody concentrations after the booster, 55.4% and 11.6% only formed neutralizing antibodies against the SARS-CoV-2 wild type and Omicron, respectively. Treatment with mycophenolic acid/mycophenolate mofetil (in strata of the dose quartiles), advanced age, and' above all' impaired renal function (eGFR <60 mL/min) adversely influenced the humoral immunity regarding seroconversion and inhibition of the wild type of SARS-CoV-2.
Conclusions: Apart from immunosuppressive therapy, the humoral vaccination response is largely affected by nonmodifiable factors in kidney transplant recipients. With the currently leading and clinically easier Omicron variant, this puts into perspective the strategy to significantly enhance the protective efficacy of the available vaccines by reducing or temporarily stopping proliferation inhibitors, not least considering the inherent rejection risk with a possible deterioration of graft function.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575732 | PMC |
| http://dx.doi.org/10.1097/TXD.0000000000001384 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of renal functional reserve with oral protein load or new ultrasound test.
J Nephrol
January 2025
Department of Medicine, Surgery and Neurosciences, Nephrology, Dialysis and Transplantation Unit, University Hospital of Siena, Siena, Italy.
Background: Renal functional reserve (RFR) measures the difference between the stimulated glomerular filtration rate (GFR) and the baseline GFR to detect early signs of renal functional decline. The protein load test (RFR-T) is the gold standard for RFR assessment but is a complicated procedure. Renal intraparenchymal resistance index (RRI) variation test (DRRI-T) is a non-invasive method to measure renal function reserve using ultrasound.
View Article and Find Full Text PDFA golden year of innovative kidney disease therapeutics.
Nat Rev Nephrol
January 2025
Department of Kidney and Transplant Services, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Efficacy and Safety of a Desensitization Treatment With Rituximab and Immunoglobulin in Hyperimmunized Patients Awaiting a Cadaveric Kidney Transplantation.
Transplant Proc
January 2025
Servicio de Nefrología, Hospital Universitario La Paz, Madrid, Spain.
Background: Patients on a kidney transplant waiting list with antibodies against more than 80% of a panel reactive antibody (PRA) are difficult to transplant, even with national or regional programs. Desensitization treatment with high-dose intravenous immunoglobulin and rituximab could be offered to patients with a long waiting time for a cadaveric donor to improve their odds of finding a kidney.
Methods: This was a retrospective, single-center study including all hyperimmunized patients on the waiting list for a cadaveric kidney donor who received a desensitization treatment between 2010 and 2020.
Hemophagocytic Lymphohistiocytosis in a Kidney Transplant Recipient: Case Report.
Transplant Proc
January 2025
Nephrology, Hospital Universitario Donostia, San Sebastián, España.
Hemophagocytic lymphohistiocytosis is a potentially fatal multisystemic inflammatory syndrome that is better understood in the pediatric population. Consequently, the diagnostic criteria for adults still derives from studies conducted in the pediatric population. Several genetic mutations and secondary causes, including infections, autoimmunity, and malignancy, have been reported as significant actors in this condition, especially in adults.
View Article and Find Full Text PDFCorrigendum to "A bioprinted and scalable model of human tubulo-interstitial kidney fibrosis" [Biomaterials, 316 (2025) 123009].
Biomaterials
January 2025
Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology, Hypertension), RWTH Aachen University Medical Faculty, Aachen, Germany; Department of Internal Medicine, Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!